Chardan Capital analyst Michael Morabito reiterated a Buy rating on NGM Biopharmaceuticals (NASDAQ:NGM) Inc on Friday, setting a price target of $39, which is approximately 104.51% above the present share price of $19.07.
Morabito expects NGM Biopharmaceuticals Inc to post earnings per share (EPS) of -$0.38 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in NGM Biopharmaceuticals, with an average price target of $32.75.
The analysts price targets range from a high of $39 to a low of $30.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $19.76 million and a net profit of -$25.53 million. The company's market cap is $1.31 billion.
According to TipRanks.com, Chardan Capital analyst Michael Morabito is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.6% and a 37.50% success rate.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.